Expanesthetics is based on a proposed answer to one of the longest-standing scientific questions in modern medicine: How do the inhaled anesthetics work? At long last, a major discovery regarding the mechanism of action of the inhaled anesthetics has shed some light on this question, and has rekindled the search for new inhaled anesthetics. Half a century after the discovery of “modern” inhaled anesthetics, Expanesthetics has discovered new inhaled anesthetics that may turn out to be significantly faster than the conventional agents – a characteristic on its own that history suggests may rapidly drive adoption. These novel anesthetics may also turn out to have several other favorable clinical qualities that are not achievable with conventional agents. Our market data suggests that such an agent, if it were to achieve regulatory and marketing approval, could make these novel agents rapidly competitive. Expanesthetics has a global exclusive license to this patented and patent-pending technology.
Expanesthetics is also developing a new class of pain drugs that was discovered serendipitously during our search for new anesthetics. Expanesthetics’ novel pain drugs could be the next evolution of pain medicine.
Come learn more about Expanesthetics and about how you can be a part of developing the next generation of inhaled anesthetics. Visit us at Booth 1647 or learn more at expanesthetics.com/ASA.
Expanesthetics is a pre-market, pre-clinical, development-stage pharmaceutical company exploring new inhaled anesthetics and analgesics. Come learn more at Booth 1647.